ArticleJTO clinical and research reports2022

A Phase 2 Study of Lorlatinib in Patients With ROS1-Rearranged Lung Cancer With Brain-Only Progression on Crizotinib.

Jaime L Schneider et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.